| Cohort | Year | Country | Test | Subjects | Positive (%) | Bibliography |
| 5.2.1 - Source Exposed (Symptoms, SPT) | 2005 | Germany | HRT | 20 | 65.000 | |
| 1.10 - Any allergy symptom, Diagnosed | 2010 | Italy | IgE | 16408 | 0.360 | 20100301, Scala E
|
| 1.2.1 - Asthma, Diagnosed (Adults) | 2012 | Sweden | IgE | 96 | 1.040 | 20120528, Patelis A
|
| 1.3 - Rhinitis, Diagnosed | 2013 | Brazil | IgE | 101 | 0.000 | 20130912, Lacerda Araujo LM
|
| 1.5 - Atopic Dermatitis, Diagnosed | 2013 | Germany | IgE | 140 | 1.430 | 20130111, Ott H
|
| 1.5 - Atopic Dermatitis, Diagnosed | 2009 | Germany | IgE | 20 | 10.000 | 20091005, Ott H
|
| 1.5 - Atopic Dermatitis, Diagnosed | 2009 | Germany | IgE | 20 | 10.000 | 20091005, Ott H
|
| 10.1 - Normal Control | 2012 | Belgium | IgE | 27 | 0.000 | 20110223, De Knop KJ
|
| 10.1 - Normal Control | 2009 | Belgium | IgE | 26 | 0.000 | 20091121, Ebo DG
|
| 4.1.4 - Heterologous Source Sensitized (Symptoms, IgE) | 2009 | Belgium | IgE | 22 | 0.000 | 20091121, Ebo DG
|
| 4.1.4 - Heterologous Source Sensitized (Symptoms, IgE) | 2012 | Denmark | IgE | 30 | 30.000 | 20120410, Ballmer-Weber BK
|
| 4.1.4 - Heterologous Source Sensitized (Symptoms, IgE) | 2012 | Spain | IgE | 20 | 0.000 | 20120410, Ballmer-Weber BK
|
| 4.1.4 - Heterologous Source Sensitized (Symptoms, IgE) | 2012 | Switzerland | IgE | 21 | 24.000 | 20120410, Ballmer-Weber BK
|
| 4.1.4 - Heterologous Source Sensitized (Symptoms, IgE) | 2005 | Switzerland | IgE | 21 | 38.100 | |
| 4.1.5 - Heterologous Source Sensitized (IgE) | 2009 | Belgium | IgE | 20 | 25.000 | 20091121, Ebo DG
|
| 4.1.5 - Heterologous Source Sensitized (IgE) | 2011 | Italy | IgE | 1084 | 6.820 | 20110211, DAvino R
|
| 4.1.6 - Heterologous Source Sensitized (High IgE) | 2011 | Austria | IgE | 60 | 28.330 | 20110211, DAvino R
|
| 4.1.6 - Heterologous Source Sensitized (High IgE) | 2011 | Italy | IgE | 214 | 20.090 | 20110211, DAvino R
|
| 4.1.7 - Heterologous Source Sensitized (Symptoms, SPT, IgE) | 2009 | Belgium | IgE | 37 | 13.510 | 20090826, Ebo DG
|
| 5.1.1 - Source Exposed (Symptoms) | 2005 | Switzerland | IgE | 40 | 97.500 | |
| 5.2.1 - Source Exposed (Symptoms, SPT) | 2005 | Germany | IgE | 20 | 75.000 | |
| 5.3.1 - Source Exposed (Symptoms, IgE) | 2012 | Belgium | IgE | 99 | 6.060 | 20110223, De Knop KJ
|
| 5.7.2 - Source Exposed (Provocation Test - Ingestion) | 2012 | Denmark | IgE | 20 | 70.000 | 20120410, Ballmer-Weber BK
|
| 5.7.2 - Source Exposed (Provocation Test - Ingestion) | 2012 | Spain | IgE | 9 | 44.000 | 20120410, Ballmer-Weber BK
|
| 5.7.2 - Source Exposed (Provocation Test - Ingestion) | 2012 | Switzerland | IgE | 20 | 95.000 | 20120410, Ballmer-Weber BK
|
| 6.2 - General Population (Adults) | 2012 | Sweden | IgE | 371 | 0.000 | 20120528, Patelis A
|
Loading...
Dau c 1
